Pacific Biosciences of Californ (PACB) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.14

Estimate

-$0.13

Surprise

-7.0%

Score at report (before → after)

4.6 → 4.8/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Pacific Biosciences of Californ (PACB) reported a wider loss than forecast — diluted EPS of -$0.14 against the -$0.13 estimate (a 7.0% shortfall). TrendMatrix's engine moved from Sell (4.6/10) to Hold at 4.8/10 after the report — the engine's score rose despite the miss.

TrendMatrix currently rates PACB Sell at 4.4/10.

3 of the last 4 quarters beat the estimate; this quarter's -7.0% surprise compares with a +6.0% four-quarter average. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$1.32

Price target

$1.88

Stop

$1.21

Upside to target

+42.4%

Reward-to-risk

3.0:1

Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Devices

Market cap

$404.1M

P/E (fwd)

-3.2

52-week range

$1.07–$2.73

Off 52-week high

51.6%

RSI (14)

47

Volume vs avg

0.61×

Score today

4.4/10